Search research articles
Contact Us
Filters
Showing results (321-330 of 361) with videos related to
Page
of 37
Sort By:
Nature Reviews. Clinical Oncology
|
March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Aakash Desai, Justin F Gainor, Aparna Hegde, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 6, 2023
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide
Stephen V Liu, Tony S K Mok, Barzin Y Nabet, et al.
Cancer Medicine
|
December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancer
David G Pfister, Robert I Haddad, Francis P Worden, et al.
Critical Reviews in Oncology/Hematology
|
October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors
George D Demetri, Filippo De Braud, Alexander Drilon, et al.
Molecular Cancer Therapeutics
|
September 14, 2021
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer
Julia Judd, Nagla Abdel Karim, Hina Khan, et al.
JCO Precision Oncology
|
February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung Cancer
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
British Journal of Cancer
|
September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
Christian Rolfo, Alexander Drilon, David Hong, et al.
Cancer Discovery
|
November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Page
of 37
Search research articles
Search
Showing results (321-330 of 361) with videos related to
Sort By:
Page
of 37
Nature Reviews. Clinical Oncology
|
March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Aakash Desai, Justin F Gainor, Aparna Hegde, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 6, 2023
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide
Stephen V Liu, Tony S K Mok, Barzin Y Nabet, et al.
Cancer Medicine
|
December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancer
David G Pfister, Robert I Haddad, Francis P Worden, et al.
Critical Reviews in Oncology/Hematology
|
October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors
George D Demetri, Filippo De Braud, Alexander Drilon, et al.
Molecular Cancer Therapeutics
|
September 14, 2021
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer
Julia Judd, Nagla Abdel Karim, Hina Khan, et al.
JCO Precision Oncology
|
February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung Cancer
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
British Journal of Cancer
|
September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
Christian Rolfo, Alexander Drilon, David Hong, et al.
Cancer Discovery
|
November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Page
of 37